中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.08.044
Research funding:

 

  • Published Date: 2020-08-20
  • The incidence rate of nonalcoholic fatty liver disease(NAFLD) is increasing year by year and NAFLD has become one of the most common liver diseases in the world.Metabolomics follows the research thoughts of genomics and proteomics and conducts a quantitative analysis of all metabolites in organisms to explore the association between metabolites and physiological and pathological changes,which provides a new way for studying the traditional Chinese medicine diagnosis and treatment of NAFLD.This article summarizes the research advances in metabolomics and traditional Chinese medicine syndromes in NAFLD,so as to provide new thoughts and methods for further exploration of NAFLD.

     

  • [1] COBBINA E,AKHLAGHI F. Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev,2017,49(2):197-211.
    [2] TU LN,SHOWALTER MR,CAJKA T,et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep,2017,7(1):6120.
    [3] CHEN F,ESMAILI S,ROGERS GB,et al. Lean NAFLD:A distinct entity shaped by differential metabolic adaptation[J].Hepatology,2020,71(4):1213-1227.
    [4] SANYAL AJ,FRIEDMAN SL,MCCULLOUGH AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop[J]. Hepatology,2015,61(4):1392-1405.
    [5] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
    [6] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol,2018,34(12):34-38.(in Chinese)李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志,2018,34(12):34-38.
    [7] ZHANG AH,SUN H,QIU S,et al. Recent highlights of metabolomics in Chinese medicine syndrome research[J]. Evid Based Complement Alternat Med,2013,2013:402159.
    [8] EVANGELATOS N,BAUER P,REUMANN M,et al. Metabolomics in sepsis and its impact on public health[J]. Public Health Genomics,2017,20(5):274-285.
    [9] LANS I,GANTNER M,MURINELLO S,et al. Metabolomics in the study of retinal health and disease[J]. Prog Retin Eye Res,2019,69:57-79.
    [10] CHEN X,YU D. Metabolomics study of oral cancers[J].Metabolomics,2019,15(2):22.
    [11] HYTYLINEN T. Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications[J]. Expert Rev Mol Diagn,2012,12(5):527-538.
    [12] NEMKOV T,REISZ JA,GEHRKE S,et al. High-throughput metabolomics:Isocratic and gradient mass spectrometrybased methods[J]. Methods Mol Biol,2019,1978:13-26.
    [13] HE J. Study on mechanism of collagen-induced arthritis(CIA)rats treated with moxibustion based on urinary metabolomics[D].Nanjing:Nanjing University of Chinese Medicine,2019.(in Chinese)何静.基于尿液代谢组学艾灸治疗胶原诱导型关节炎大鼠的作用机制研究[D].南京:南京中医药大学,2019.
    [14] KHUSIAL RD,CIOFFI CE,CALTHARP SA,et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics[J]. Hepatol Commun,2019,3(10):1311-1321.
    [15] LI J,ZHAO Y,HUANG C,et al. Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease[J].Endocr Connect,2019,8(4):299-308.
    [16] KALHAN SC,GUO L,EDMISON J,et al. Plasma metabolomic profile in nonalcoholic fatty liver disease[J]. Metabolism,2011,60(3):404-413.
    [17] DONG S,ZHAN ZY,CAO HY,et al. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease[J]. World J Gastroenterol,2017,23(15):2771-2784.
    [18] MICCHELI A,CAPUANI G,MARINI F,et al. Urinary(1)HNMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment[J]. Int J Obes(Lond),2015,39(7):1118-1125.
    [19] VINAIXA M,RODRGUEZ MA,RULL A,et al. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease[J]. J Proteome Res,2010,9(5):2527-2538.
    [20] LI ZH,ZHANG N,WANG Y,et al. Mechanism of Yinchenhao Decoction in treating non-alcoholic fatty liver based on 16S rRNA technique and metabonomics[J]. Chin J Tradit Chin Med Pharm,2019,34(5):1908-1913.(in Chinese)李自辉,张娜,王宇,等.基于16S rRNA技术与代谢组学探究茵陈蒿汤治疗非酒精性脂肪肝的作用机制[J].中华中医药杂志,2019,34(5):1908-1913.
    [21] FAN SC,GAO Y,ZHANG HZ,et al. Untargeted and targeted metabolomics and their applications in discovering drug targets[J]. Prog in Pharm Sci,2017,41(4):263-269.(in Chinese)范仕成,高悦,张慧贞,等.非靶向和靶向代谢组学在药物靶点发现中的应用[J].药学进展,2017,41(4):263-269.
    [22] JOHNSON CH,IVANISEVIC J,SIUZDAK G. Metabolomics:Beyond biomarkers and towards mechanisms[J]. Nat Rev Mol Cell Biol,2016,17(7):451-459.
    [23] FELDMAN A,EDER SK,FELDER TK,et al. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver:A targeted metabolomics approach[J]. Diabetes Metab,2019,45(2):132-139.
    [24] PAPANDREOU C,BULLM,TINAHONES FJ,et al. Serum metabolites in non-alcoholic fatty-liver diease development or reversion; a targeted metabolomic approach within the PREDIMED trial[J]. Nutr Metab,2017,14:58.
    [25] XU Y,HAN J,DONG J,et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J]. Int J Mol Sci,2019,20(5):1220.
    [26] ZHU H,WANG Z,WU Y,et al. Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease[J]. Int J Biol Macromol,2019,128:363-375.
    [27] SETHI S,BRIETZKE E. Recent advances in lipidomics:Analytical and clinical perspectives[J]. Prostaglandins Other Lipid Mediat,2017,128-129:8-16.
    [28] YANG RX,HU CX,MI YQ,et al. A serum lipidomic study of patients with non-alcoholic fatty liver disease[J]. Chin J Hepatol,2017,25(2):122-127.(in Chinese)杨蕊旭,胡春秀,宓余强,等.非酒精性脂肪性肝病患者血清脂质组学研究[J].中华肝脏病杂志,2017,25(2):122-127.
    [29] FENG S,GAN L,YANG CS,et al. Effects of stigmasterol andβ-sitosterol on nonalcoholic fatty liver disease in a mouse model:A lipidomic analysis[J]. J Agric Food Chem,2018,66(13):3417-3425.
    [30] PREUSS C,JELENIK T,BDIS K,et al. A new targeted lipidomics approach reveals lipid droplets in liver,muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver[J]. Cells,2019,8(3):277.
    [31] WANG J,MA Q,LI Y,et al. Research progress on traditional Chinese medicine syndromes of diabetes mellius[J]. Biomed Pharmacother,2020,121:109565.
    [32] GU LM,CAO PR,GU C. Correlation between traditional Chinese medicine syndrome and clinical biochmical indexes of non-alcoholic fatty liver[J]. J Nanjing Univ Tradit Chin Med,2019,35(6):738-740.(in Chinese)顾立梅,曹培让,顾超.非酒精性脂肪肝中医证型及临床生化指标相关性研究[J].南京中医药大学学报,2019,35(6):738-740.
    [33] LI ZG,JIANG HX,JIAO YT. Literary analysis on distribution of traditional Chinese medicine syndromes of non-alcoholic fatty liver disease[J]. Chin J Tradit Chin Med Pharm,2017,32(10):4713-4715.(in Chinese)李志国,姜韩雪,焦云涛.非酒精性脂肪性肝病中医证型分布的文献分析[J].中华中医药杂志,2017,32(10):4713-4715.
    [34] MA X,GU HT,ZHAO Y. Serum metabolomics study on nonalcoholic fatty liver disease with liver damage of different syndromes[J]. Chin J Tradit Chin Med Pharm,2017,32(3):1246-1250.(in Chinese)马欣,顾宏图,赵瑜.不同证候的非酒精性脂肪肝合并肝损伤患者的血清代谢组学分析[J].中华中医药杂志,2017,32(3):1246-1250.
    [35] DAI J,SUN S,CAO J,et al. Similar connotation in chronic hepatitis B and nonalcoholic fatty liver patients with dampness-heat syndrome[J]. Evid Based Complement Alternat Med,2013,2013:793820.
    [36] GUAN W,LI RY,GUO JL. Analysis of mechanism of Xiaoyaowan on rats with nonalcoholic fatty liver disease and syndrome of liver depression and spleen deficiency by1H-NMR metabolomic[J].Chin J Exp Tradit Med Form,2019,24(19):99-111.(in Chinese)关伟,李若瑜,郭继龙.基于1H-NMR代谢组学技术分析逍遥丸干预非酒精性脂肪肝肝郁脾虚证大鼠的作用机制[J].中国实验方剂学杂志,2019,24(19):99-111.
    [37] LI RY,MIAO YC,LI ML. Urinary metabolomic study on liver depression and spleen deficiency syndrome of nonalcoholic fatty liver in rats[J]. Chin J Basic Med Tradit Chin Med,2019,24(19):99-111.(in Chinese)李若瑜,庙宇船,李明磊.大鼠非酒精性脂肪肝肝郁脾虚证的尿液代谢组学研究[J].中国中医基础医学杂志,2019,24(19):99-111.
  • Relative Articles

    [1]Huajie XIE, Kai CHANG, Yanyan WANG, Wanlin NA, Huan CAI, Xia LIU, Zhongyong JIANG, Zonghai HU, Yuan LIU. Characteristics of mitochondrial translational initiation factor 2 gene methylation and its association with the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2025, 41(2): 284-291. doi: 10.12449/JCH250214
    [2]Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
    [3]Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
    [4]Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
    [5]Kaifu LI, Yongcheng TANG, Hao TANG, Xi ZHANG, Benjian GAO, De LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1397-1403. doi: 10.12449/JCH240718
    [6]Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. Journal of Clinical Hepatology, 2023, 39(12): 2782-2792. doi: 10.3969/j.issn.1001-5256.2023.12.006
    [7]Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
    [8]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis: Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [9]Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma: Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
    [10]Ke MA, Lijin ZHAO. Role of N6-methyladenosine in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2210-2214. doi: 10.3969/j.issn.1001-5256.2021.09.042
    [11]Yanzhen MA, Furong WU, Jiafu ZHANG, Chang FAN, Shaopeng HUANG, Sen CHEN, Hui JIANG. Role of N6-methyladenosine methylation in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(11): 2719-2722. doi: 10.3969/j.issn.1001-5256.2021.11.051
    [12]Zhou Yan, Ning Bo. Application of abnormal cell-free DNA methylation in pancreatic juice in the early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2145-2148. doi: 10.3969/j.issn.1001-5256.2020.09.054
    [13]Liu Tao, Xu QiuLing. Spleen-strengthening and dampness-removing therapy exerts a therapeutic effect on nonalcoholic fatty liver disease by regulating hepatic MTP promoter methylation[J]. Journal of Clinical Hepatology, 2019, 35(3): 661-664. doi: 10.3969/j.issn.1001-5256.2019.03.047
    [14]Kang YanHong, Li Wei, Zhan WeiLi, Shang Jia, Yang Lin. Effects of HBV X protein on expression and promoter methylation of p16 tumor suppressor gene[J]. Journal of Clinical Hepatology, 2016, 32(3): 484-487. doi: 10.3969/j.issn.1001-5256.2016.03.017
    [16]Zhang JiCai, Yu ZongTao, Lyu Jun, Li HaiPing, Gao Bo. Relationship between HBV infection and DNMT expression in liver cancer tissues[J]. Journal of Clinical Hepatology, 2013, 29(8): 620-623. doi: 10.3969/j.issn.1001-5256.2013.08.017
    [17]Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018
    [18]Zhang HuiJing, Li ShengMian. Promoter methylation in APC, RASSF1A, WIF-1 gene in digestive system tumors[J]. Journal of Clinical Hepatology, 2011, 27(4): 429-432.
    [19]Xiong QiXiang, Xiong LiJuan. Hepatitis B virus infection and DNA methylation in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(8): 881-884.
    [20]Zhang JunXia, Wang Yan, Zhao YanPing, Zhang Bei, Li Jia, Huang Jian. p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China[J]. Journal of Clinical Hepatology, 2011, 27(10): 1051-1054.
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 10.1 %FULLTEXT: 10.1 %META: 86.8 %META: 86.8 %PDF: 3.2 %PDF: 3.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.9 %其他: 5.9 %其他: 0.8 %其他: 0.8 %China: 0.4 %China: 0.4 %Doylestown: 0.2 %Doylestown: 0.2 %India: 0.2 %India: 0.2 %[]: 0.6 %[]: 0.6 %上海: 5.5 %上海: 5.5 %保定: 0.2 %保定: 0.2 %北京: 15.1 %北京: 15.1 %南宁: 0.2 %南宁: 0.2 %吉林: 0.8 %吉林: 0.8 %哥伦布: 0.2 %哥伦布: 0.2 %宰加济格: 0.2 %宰加济格: 0.2 %张家口: 2.5 %张家口: 2.5 %昆明: 0.6 %昆明: 0.6 %杭州: 0.2 %杭州: 0.2 %武汉: 0.4 %武汉: 0.4 %福州: 0.2 %福州: 0.2 %芒廷维尤: 34.2 %芒廷维尤: 34.2 %芝加哥: 0.4 %芝加哥: 0.4 %苏州: 0.4 %苏州: 0.4 %莫斯科: 1.5 %莫斯科: 1.5 %西宁: 26.9 %西宁: 26.9 %贵港: 0.2 %贵港: 0.2 %郑州: 0.6 %郑州: 0.6 %重庆: 0.2 %重庆: 0.2 %长春: 0.8 %长春: 0.8 %长治: 0.2 %长治: 0.2 %其他其他ChinaDoylestownIndia[]上海保定北京南宁吉林哥伦布宰加济格张家口昆明杭州武汉福州芒廷维尤芝加哥苏州莫斯科西宁贵港郑州重庆长春长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1014) PDF downloads(183) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return